Re-engineering Cytotoxic Therapy
for Familial HLH
Transforming established Topoisomerase II inhibitors into precision-engineered therapies through advanced delivery architectures.
From systemic toxicity to targeted activation — unlocking the next generation of HLH treatment.
The Clinical Challenge
A life-threatening disease constrained
by toxic therapy
Familial Hemophagocytic Lymphohistiocytosis (HLH) is a rapidly progressive, immune-driven condition requiring aggressive cytotoxic intervention. Current treatment paradigms rely heavily on etoposide and related agents, which:
The fundamental challenge
Not efficacy—
but precision delivery.
Our Approach
From cytotoxicity to
controlled activation
We are reimagining the use of Topoisomerase II inhibitors through advanced delivery systems — this is fundamentally an engineering and formulation challenge, not just medicinal chemistry.
Antibody-Drug Conjugates
Combining monoclonal antibodies with highly potent cytotoxic payloads, enabling targeted delivery to disease-driving cells with precision activation.
Tumour / Target-Activated Prodrugs
Chemically masked agents that remain inert in circulation and activate selectively within disease-specific microenvironments.
Why This Is Hard
The frontier of
stability-driven formulation
Both ADCs and prodrugs require the same fundamental paradox — achieving this balance defines the pinnacle of CMC innovation.
During Storage & Circulation
Must remain completely inert — no premature degradation, no early activation, no loss of structural integrity.
At the Target Site
Must become highly active — precise, controlled release in the specific biological environment of disease-driving cells.
Antibody-Drug Conjugates
Where biologics meet
highly potent payloads
ADCs represent one of the most complex challenges in pharmaceutical development — combining monoclonal antibodies with highly potent cytotoxic agents.
CHALLENGE 01
Linker Stability & Excipient Engineering
- Must remain stable during storage and systemic circulation
- Must cleave precisely within target cells (e.g., lysosomal environment)
- Requires formulation systems that prevent premature hydrolysis
CHALLENGE 02
Drug-to-Antibody Ratio (DAR) Control
- Too high → aggregation, instability, precipitation
- Too low → reduced efficacy and therapeutic effect
- Requires tight process control and batch consistency
Tumour-Activated Prodrugs
Precision masking of
highly potent molecules
Prodrugs offer a chemically driven alternative to targeted delivery, requiring a sophisticated balance between stability and controlled activation.
CHALLENGE 01
Controlled Activation
- Masking groups must remain stable in formulation and circulation
- Activation must occur only in disease-specific environments (e.g., proteases)
CHALLENGE 02
Formulation-Dependent Stability
- Protection of cleavage sites from hydrolysis
- Ensuring predictable activation kinetics across dosing conditions
CHALLENGE 03
The Solubility Barrier
- Topoisomerase II inhibitors are inherently poorly soluble
- Modifications often worsen solubility further
The Core Problem We Solve
Solving the solubility–toxicity
paradox
Cytotoxic agents face two fundamental barriers. Our work focuses on engineering solutions that address both simultaneously.
Solubility Without Risk
Enhancing solubility without hypersensitivity-inducing excipients that compromise patient safety.
Targeted Delivery Systems
Engineering delivery systems that minimise systemic exposure and concentrate activity at the disease site.
Reduced Myelosuppression
Enabling targeted activation to reduce the bone marrow toxicity that constrains current dosing strategies.
Molecules in Focus
Building on clinically validated
cytotoxic scaffolds
We are exploring the re-engineering of established agents — clinically proven, mechanistically validated, and limited primarily by delivery and toxicity, not efficacy.
Epipodophyllotoxins
Anthracyclines
Anthracenediones
The SynapTx Advantage
From trial-and-error to
predictive CMC
Most AI platforms in drug development focus on target discovery or clinical data analysis. SynapTx is designed differently — as a CMC-focused intelligence layer for formulation science.
Integrated datasets
SynapTx enables
Translational Impact
Redefining therapeutic windows
in HLH
By combining advanced delivery systems, formulation innovation, and predictive modelling through SynapTx, we aim to transform HLH treatment outcomes.
Reduce Systemic Toxicity
Lower off-target effects through targeted delivery architectures
Improve Targeting Precision
Direct cytotoxic activity to disease-driving immune cells
Enable Safer Dosing
Expand the therapeutic window for more flexible dosing strategies
Expand Clinical Applicability
Extend platform utility across HLH and related indications
Strategic Positioning
Engineering the future of
cytotoxic therapy
This programme represents a fundamental shift in how cytotoxic medicines are conceived, formulated, and delivered.
Partner With Us
Partner with us to redefine
HLH therapy
We are actively seeking collaborators to advance next-generation delivery systems for cytotoxic agents in HLH and related indications.
Partner or Collaborate With Us